
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
Combination Chemotherapy in Advanced Hepatocellular Carcinoma
1 Department of Surgery and Clinical Oncology, Graduate School of Medicine, Osaka University, Osaka, Japan; and 2 Taisho Laboratory of Functional Genomics and 3 Laboratory of Theoretical Life Science, Nara Institute of Science and Technology, Nara, Japan
ABSTRACT
Purpose: The prognosis of hepatocellular carcinoma (HCC) is very poor, particularly in patients with tumors that have invaded the major branches of the portal vein. Combination chemotherapy with intra-arterial 5-fluorouracil and subcutaneous interferon-
has shown promising results for such advanced HCC, but it is important to develop the ability to accurately predict chemotherapeutic responses.
Experimental Design: We analyzed the expression of 3,080 genes using a polymerase chain reaction-based array in 20 HCC patients who were treated with combination chemotherapy after reduction surgery. After unsupervised analyses, a supervised classification method for predicting chemotherapeutic responses was constructed. To minimize the number of predictive genes, we used a random permutation test to select only significant (P < 0.01) genes. A leave-one-out cross-validation confirmed the gene selection. We also prepared an additional 11 cases for validation of predictive performance.
Results: Hierarchical clustering analysis and principal component analysis with all 3,080 genes revealed distinct gene expression patterns in responders (those with complete response or partial response) and nonresponders (those with stable disease or progressive disease) to the combination chemotherapy. Using a weighted-voting classification method with either all genes or only significant genes as assessed by permutation testing, the objective responses to treatment were correctly predicted in 17 of 20 cases (accuracy, 85%; positive predictive value, 100%; negative predictive value, 80%). Moreover, patients in the validation dataset could be classified into two distinct prognostic groups using 63 predictive genes.
Conclusions: Molecular analysis of 63 genes can predict the response of patients with advanced HCC and major portal vein tumor thrombi to combination chemotherapy with 5-fluorouracil and interferon-
.
This article has been cited by other articles:
![]() |
R. W. C. Pang, J. W. Joh, P. J. Johnson, M. Monden, T. M. Pawlik, and R. T. P. Poon Biology of Hepatocellular Carcinoma Ann. Surg. Oncol., April 1, 2008; 15(4): 962 - 971. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Shirahata, K. Iwao-Koizumi, S. Saito, N. Ueno, M. Oda, N. Hashimoto, J. A. Takahashi, and K. Kato Gene Expression-Based Molecular Diagnostic System for Malignant Gliomas Is Superior to Histological Diagnosis Clin. Cancer Res., December 15, 2007; 13(24): 7341 - 7356. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. K. Abou-Alfa, L. Schwartz, S. Ricci, D. Amadori, A. Santoro, A. Figer, J. De Greve, J.-Y. Douillard, C. Lathia, B. Schwartz, et al. Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma J. Clin. Oncol., September 10, 2006; 24(26): 4293 - 4300. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. N. Vemuri and A. A. Aristidou Metabolic Engineering in the -omics Era: Elucidating and Modulating Regulatory Networks Microbiol. Mol. Biol. Rev., June 1, 2005; 69(2): 197 - 216. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |